Immunoregulatory effects of treatment with mesenchymal stem cells on T-cell activity in cirrhosis
Célula madre mesenquimatosa (MSC) therapy’s immunomodulatory impact on T-cell activity in cirrhosis is analyzed. This article explores how MSC treatment modifies T-cell responses, potentially offering novel therapeutic strategies for managing cirrhosis-related immune dysfunction. {CONTENIDO} reveals key findings.




